Početna stranicaDVA • NYSE
add
Davita Inc
151,85 $
Poslije radnog vremena:(0,00 %)0,00
151,85 $
Zatvoreno: 24. tra, 17:57:32 GMT -4 · USD · NYSE · Odricanje od odgovornosti
Preth. zaklj. cijena
155,03 $
Dnevni raspon
149,99 $ - 154,45 $
Godišnji raspon
101,00 $ - 159,42 $
Tržišna kapitalizacija
10,01 mlr. USD
Prosječna količina
797,21 tis.
P/E omjer
15,96
Prinos dividende
-
Glavno tržište vrijednosnica
NYSE
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | pro 2025.info | Godišnja promjena |
|---|---|---|
Prihod | 3,62 mlr. | 9,87 % |
Operativni troškovi | 659,06 mil. | 11,97 % |
Neto dohodak | 234,22 mil. | −9,68 % |
Neto profitabilnost | 6,47 | −17,79 % |
Zarada po dionici | 3,40 | 51,79 % |
EBITDA | 737,91 mil. | 12,69 % |
Efektivna porezna stopa | 20,05 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | pro 2025.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 700,74 mil. | −17,17 % |
Ukupna imovina | 17,48 mlr. | 1,13 % |
Ukupne obveze | 16,32 mlr. | 7,42 % |
Ukupni kapital | 1,16 mlr. | — |
Dionice u optjecaju | 66,80 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | −16,32 | — |
Povrat imovine | 7,87 % | — |
Povrat kapitala | 9,79 % | — |
Tok novca
Neto promjena novca
| (USD) | pro 2025.info | Godišnja promjena |
|---|---|---|
Neto dohodak | 234,22 mil. | −9,68 % |
Gotovina od poslovanja | 540,73 mil. | −1,26 % |
Gotovina iz ulaganja | −163,13 mil. | 34,22 % |
Gotovina iz financiranja | −414,52 mil. | 26,65 % |
Neto promjena novca | −37,67 mil. | 86,49 % |
Slobodan tok novca | 395,96 mil. | 16,37 % |
Više
DaVita Inc., incorporated in Delaware and headquartered in Denver, provides kidney dialysis services through a network of 2,657 outpatient centers in the United States, serving 200,500 patients, and 585 outpatient centers in 14 other countries serving 94,500 patients. The company primarily treats end-stage renal disease, which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation.
In 2025, 68% of the company's revenues came from Medicare and other government-based health insurance programs. In 2025, 89% of the company's patients were covered by government-based health insurance programs. Commercial payers, which accounted for 32% of revenues in 2025, generate nearly all of the company's profit as they reimburse at a much higher rate than government-based health insurance programs.
The company is ranked 331st on the Fortune 500. Wikipedia
Glavni izvršni direktor
Osnovano
1992
Web-lokacija
Zaposlenici
78.000